TAK-063 is primarily investigated for its potential therapeutic application in the treatment of schizophrenia. It functions as a selective phosphodiesterase 10A (PDE10A) inhibitor, which increases levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in the brain—molecules involved in neuronal signaling. By modulating these pathways, TAK-063 has shown promise in preclinical studies for improving both positive and negative symptoms of schizophrenia, as well as cognitive impairments associated with the disorder. Its development represents a novel approach in antipsychotic therapy, targeting intracellular signaling rather than dopamine or serotonin receptors directly. TAK-063 has advanced into clinical trials to evaluate its efficacy, safety, and pharmacokinetic profile in humans.